All sp:Sydnexis Articles
-
591ClinicalWorking Toward an Approved Pharmacological Treatment for Myopia Management
sponsored content December 16, 2024 Privately held, clinical-stage pharmaceutical company, Sydnexis Inc. has recently completed an evaluation of its patented low-dose atropine...
-
1.3KClinicalLow-Dose Atropine: An Effective and Safe Option for Managing Juvenile-onset Myopia
sponsored content March 1, 2024 The evidence supporting the use of topical low-dose atropine in treating juvenile-onset myopia is so strong that...
-
2.1KClinicalSafe and Effective Low-Dose Atropine Can Be Stable and Comfortable Too
sponsored content August 15, 2023 Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence...